TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
SOPHIA ANTIPOLIS, France, Aug. 10, 2016 -- Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic company, today announced the completion of the transfer of its European and International commercial operations and related late-stage development programs to a newly-founded, private, pan-European ophthalmic specialty pharmaceutical company. This transfer includes the affiliates Nicox Pharma (France), together with its Spanish and UK operations, Nicox GmbH (Germany), Laboratoires Nicox (France) and Nicox Farma (Italy), all commercial products and the rights (and associated agreements) to AzaSite®, AzaSite Xtra®, BromSiteTM for Europe, Middle East and Africa and NCX 4240 outside of Japan and North America. No other Nicox affiliates, operations or programs are included in or affected by this transaction.
Nicox will receive a €9 million cash payment from GHO Capital as a result of the completion of this transaction. For further information on the transaction, please refer to Nicox's Press Release dated July 5, 2016.
...................................
About Nicox
Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an international R&D company focused on the ophthalmic market. For more information on Nicox, its products or pipeline, please visit: www.nicox.com.
...................................
|
Analyst coverage Bryan, Garnier & Co Hugo Solvet Paris, France Invest Securities Martial Descoutures Paris, France Gilbert Dupont Damien Choplain Paris, France Stifel Max Hermann London, UK |
Upcoming financial and business conferences
September 11-13 Rodman & Renshaw Annual Global Investment Conference New York, US
October 5-6 Large & Midcap Event Paris, France
November 15-16 Stifel 2016 Healthcare Conference New York, US
November 18-19 Actionnaria Paris, France
November 21-23 Deutsches Eigenkapitalforum Frankfurt, Germany
December 13 Guggenheim Securities 4th Annual Boston Healthcare Conference Boston, US
...................................
Contacts
Nicox Gavin Spencer | Executive Vice President Corporate Development
Tel +33 (0)4 97 24 53 00 | [email protected]
Media Relations
United Kingdom Jonathan Birt
Tel +44 7860 361 746 | [email protected]
France NewCap | Nicolas Merigeau
Tel +33 (0)1 44 71 94 98 | [email protected]
United States Argot Partners | Eliza Schleifstein
Tel +1 (917) 763-8106 | [email protected]
Investor Relations
Europe NewCap | Julien Perez | Valentine Brouchot
Tel +33 (0)1 44 71 94 94 | [email protected]
United States Argot Partners | Melissa Forst
Tel +1 (212) 600-1902 | [email protected]
...................................
The information contained in this document may be modified without former notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.
Press release http://hugin.info/143509/R/2034162/757530.pdf
HUG#2034162
